Serum levels of chemokine (C-X-C motif) ligand 9 (CXCL9) are associated with tumor progression and treatment outcome in patients with oral cavity squamous cell carcinoma

Oral Oncology

Volumn 49, Issue 8, 2013, Pages 802-807

  Chang, Kai Ping ^a,b,c   Wu, Chih Ching ^b   Fang, Ku Hao ^a   Tsai, Chi Ying ^a   Chang, Yu Liang ^a   Liu, Shiau Chin ^a   Kao, Huang Kai ^a,c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Chemokine; CXCL9; Head and neck; Oral cancer; OSCC; Squamous cell carcinoma

Indexed keywords

CXCL9 CHEMOKINE;

ARTICLE; BLOOD LEVEL; CANCER CELL; CANCER PROGNOSIS; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOUTH SQUAMOUS CELL CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH;

CHEMOKINE; CXCL9; HEAD AND NECK; ORAL CANCER; OSCC; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CHEMOKINE CXCL9; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE KNOCKDOWN TECHNIQUES; HUMANS; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; RNA INTERFERENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84880073047     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2013.05.006     Document Type: Article

References (32)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2 2005 74 108
2. B.C. Reid, D.M. Winn, D.E. Morse, and D.G. Pendrys Head and neck in situ carcinoma: incidence, trends, and survival Oral Oncol 36 5 2000 414 420
3. I. Kodani, K. Shomori, M. Osaki, I. Kuratate, K. Ryoke, and H. Ito Expression of minichromosome maintenance 2 (MCM2), Ki-67, and cell-cycle-related molecules, and apoptosis in the normal-dysplasia-carcinoma sequence of the oral mucosa Pathobiology 69 3 2001 150 158
4. S.M. Lippman, J. Sudbo, and W.K. Hong Oral cancer prevention and the evolution of molecular-targeted drug development J Clin Oncol 23 2 2005 346 356
5. S. Silverman Jr., M. Gorsky, and F. Lozada Oral leukoplakia and malignant transformation. A follow-up study of 257 patients Cancer 53 3 1984 563 568
6. J. Sudbo Novel management of oral cancer: a paradigm of predictive oncology Clin Med Res 2 4 2004 233 242
7. I. van der Waal Potentially malignant disorders of the oral and oropharyngeal mucosa; present concepts of management Oral Oncol 46 6 2010 423 425
8. P.A. Reichart, and H.P. Philipsen Oral erythroplakia - a review Oral Oncol 41 6 2005 551 561
9. J.J. Oppenheim, W.J. Murphy, O. Chertox, V. Schirrmacher, and J.M. Wang Prospects for cytokine and chemokine biotherapy Clin Cancer Res 3 1997 2682 2686
10. A.P. Vicari, and C. Caux Chemokines in cancer Cytokine Growth Factor Rev 13 2 2002 143 154
11. A. Zlotnik Chemokines in neoplastic progression Semin Cancer Biol 14 3 2004 181 185
12. Z. Serefoglou, C. Yapijakis, E. Nkenke, and E. Vairaktaris Genetic association of cytokine DNA polymorphisms with head and neck cancer Oral Oncol 44 12 2008 1093 1099
13. P. Meisel, B. Holtfreter, R. Biffar, W. Suemnig, and T. Kocher Association of periodontitis with the risk of oral leukoplakia Oral Oncol 48 9 2012 859 863
14. K.P. Chang, Y.T. Chang, C.T. Liao, T.C. Yen, I.H. Chen, and Y.L. Chang Prognostic cytokine markers in peripheral blood for oral cavity squamous cell carcinoma identified by multiplexed immunobead-based profiling Clin Chim Acta 412 11-12 2011 980 987
15. C.T. Liao, J.T. Chang, H.M. Wang, S.H. Ng, C. Hsueh, and L.Y. Lee Surgical outcome of T4a and resected T4b oral cavity cancer Cancer 107 2 2006 337 344
16. C.T. Liao, S.F. Huang, I.H. Chen, J.T. Chang, H.M. Wang, and S.H. Ng Risk stratification of patients with oral cavity squamous cell carcinoma and contralateral neck recurrence following radical surgery Ann Surg Oncol 16 1 2009 159 170
17. K.P. Chang, S.P. Hao, C.T. Liu, M.H. Cheng, Y.L. Chang, and Y.S. Lee Promoter polymorphisms of DNMT3B and the risk of head and neck squamous cell carcinoma in Taiwan: a case-control study Oral Oncol 43 4 2007 345 351
18. K.H. Fang, H.K. Kao, M.H. Cheng, Y.L. Chang, N.M. Tsang, and Y.C. Huang Histological differentiation of primary oral squamous cell carcinomas in an area of betel quid chewing prevalence Otolaryngol Head Neck Surg 141 6 2009 743 749
19. K.P. Chang, H.K. Kao, Y. Liang, M.H. Cheng, Y.L. Chang, and S.C. Liu Overexpression of activin A in oral squamous cell carcinoma: association with poor prognosis and tumor progression Ann Surg Oncol 17 7 2010 1945 1956
20. A. Antonelli, S.M. Ferrari, S. Frascerra, A. Di Domenicantonio, A. Nicolini, and P. Ferrari Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis J Clin Endocrinol Metab 96 6 2011 1859 1863
21. B.J. Rabquer, P. Tsou, Y. Hou, E. Thirunavukkarasu, 3rd Haines GK, and A.J. Impens Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis Arthritis Res Ther 13 1 2011 R18
22. K.P. Chang, Y.T. Chang, C.C. Wu, Y.L. Liu, M.C. Chen, and N.M. Tsang Multiplexed immunobead-based profiling of cytokine markers for detection of nasopharyngeal carcinoma and prognosis of patient survival Head Neck 33 6 2011 886 897
23. H.A. Wolff, D. Rolke, M. Rave-Frank, M. Schirmer, W. Eicheler, and A. Doerfler Analysis of chemokine and chemokine receptor expression in squamous cell carcinoma of the head and neck (SCCHN) cell lines Radiat Environ Biophys 50 1 2011 145 154
24. A. Ben-Baruch The multifaceted roles of chemokines in malignancy Cancer Metastasis Rev 25 3 2006 357 371
25. C. Liu, D. Luo, B.A. Reynolds, G. Meher, A.R. Katritzky, and B. Lu Chemokine receptor CXCR3 promotes growth of glioma Carcinogenesis 32 2 2011 129 137
26. K. Ohshima, H. Suefuji, K. Karube, M. Hamasaki, B. Hatano, and T. Tutiya Expression of chemokine receptor CXCR3 and its ligand, mig, in gastric and thyroid marginal zone lymphomas. Possible migration and autocrine mechanism Leuk Lymphoma 44 2 2003 329 336
27. P. Sreekanthreddy, H. Srinivasan, D.M. Kumar, M.B. Nijaguna, S. Sridevi, and M. Vrinda Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis Cancer Epidemiol Biomarkers Prev 19 6 2010 1409 1422
28. T. Suyama, M. Furuya, M. Nishiyama, Y. Kasuya, S. Kimura, and T. Ichikawa Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma Cancer 103 2 2005 258 267
29. E. Ruiz-Garcia, V. Scott, C. Machavoine, J.M. Bidart, L. Lacroix, and S. Delaloge Gene expression profiling identifies Fibronectin 1 and CXCL9 as candidate biomarkers for breast cancer screening Br J Cancer 102 3 2010 462 468
30. S. Amatschek, R. Lucas, A. Eger, M. Pflueger, H. Hundsberger, and C. Knoll CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells Br J Cancer 104 3 2011 469 479
31. K. Kawada, M. Sonoshita, H. Sakashita, A. Takabayashi, Y. Yamaoka, and T. Manabe Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes Cancer Res 64 11 2004 4010 4017
32. T.C. Walser, S. Rifat, X. Ma, N. Kundu, C. Ward, and O. Goloubeva Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer Cancer Res 66 15 2006 7701 7707